Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05157425
Other study ID # AB-FLUVAC21
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 26, 2021
Est. completion date May 31, 2022

Study information

Verified date July 2022
Source AB Biotics, SA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized clinical trial to determine whether a probiotic formulation containing 4 probiotic strains which belong to Lactiplantibacillus plantarum and Pediococcus acidilactici species can boost the immune response to influenza vaccination evaluated at 4 weeks in a population between 50 and 80 years of age. Secondary outcomes comprise evaluation of immune response at 8 weeks after vaccination, percentage of patients with seroconversion, incidence and duration of influenza-like infections and respiratory infections throughout a 4-month period and safety.


Description:

Double blind, randomized, placebo-controlled clinical trial to determine whether supplementation with a probiotic formulation containing 4 probiotic strains (L. plantarum CECT 30292, CECT7484, CECT7485 and P. acidilactici CECT7483) can improve immune response to seasonal influenza vaccination. Subjects with age comprised between 50 and 80 years who meet inclusion and exclusion criteria will be randomized 1:1 to one of the following study groups: one will receive probiotic formulation for 28 days (1 capsule/day) and the other will receive placebo, starting the same day of the influenza vaccination. Main study outcome will be immune response at 4 weeks after vaccination, which will be determined by analysis of specific IgG antibodies in serum against influenza A and B. Secondary outcomes comprise serum titers of specific IgG at 8 weeks after vaccination, percentage of patients with seroconversion at 4 and 8 weeks, evaluation of influenza-like infections or respiratory infections throughout a 4-month period and adverse events.


Recruitment information / eligibility

Status Completed
Enrollment 140
Est. completion date May 31, 2022
Est. primary completion date February 28, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 80 Years
Eligibility Inclusion Criteria: - Subjects 50 - 80 years old receiving seasonal Influenza vaccine in season 2021-2022 - Body mass index (BMI) 18.5-34.9 kg/m2 - Willing to provide informed consent - Able to follow study procedures, according to the criteria of study investigator Exclusion Criteria: - Hypersensitivity to any of the components of influenza vaccine - Previous influenza infection in the same season (from 01/09/2021) - Having received influenza vaccination in the previous season less than 9 months before study entry (from 01/01/2021) - Having received another vaccine -different from COVID19 vaccine- up to 1 month before study inclusion or planning to receive it 1 month after study inclusion - Active infection at the moment of study entry as diagnosed by study physician - History of severe allergic reactions (food and non-food), including severe asthma. - Receiving immunosuppressant therapy, displaying neutropenia, lymphopenia, AIDS, immunoglobulin deficiency, active oncological disease. - Daily ingestion of any food complement or food added with probiotics (including Actimel o similar products) 2 weeks before inclusion in the study - Acute pancreatitis, short bowel syndrome or active inflammatory bowel disease - Diagnosed from other pathologies that according to study physician may compromise the immunological function of the individual (such as immunodeficiencies, lupus, multiple sclerosis, among others) - Having received antibiotic treatment in the previous month Exclusion criteria during the study: - Withdrawal from the study as per study investigator criteria, in case that study procedures are not followed by the participant - In case of adverse event that prevents them from following study procedures or complying with the treatments under study. - Failure to comply with study procedures: Complete less than 70% of the days in the patient's diary and/or take less than 80% of the days of the study products. - Receive any of the unauthorized treatments indicated in the selection criteria, with the exception of antibiotics that will be allowed under medical prescription.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Food Supplement
Probiotic multistrain formulation containing Lactiplantibacillus plantarum CECT30292, CECT7484, CECT7485 and P. acidilactici CECT7483 for 28 days, starting the same day of influenza vaccination
Placebo
One maltodextrin-containing capsule/day for 28 days, starting the same day of influenza vaccination

Locations

Country Name City State
Spain FIBAO- Fundación para la Investigación Biosanitaria de Andalucia Oriental Granada
Spain Hospital General de Granollers Granollers Barcelona
Spain Hospital Parc Tauli Sabadell Barcelona
Spain IDIAP Jordi Gol-Centro de Atención Primaria La Mina Sant Adrià De Besòs Barcelona
Spain Mutua de Terrassa Terrassa Barcelona

Sponsors (1)

Lead Sponsor Collaborator
AB Biotics, SA

Country where clinical trial is conducted

Spain, 

References & Publications (8)

Darbandi A, Asadi A, Ghanavati R, Afifirad R, Darb Emamie A, Kakanj M, Talebi M. The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010-20. Int J Infect Dis. 2021 Apr;105:91-104. doi: 10.1016/j.ijid — View Citation

Harper A, Vijayakumar V, Ouwehand AC, Ter Haar J, Obis D, Espadaler J, Binda S, Desiraju S, Day R. Viral Infections, the Microbiome, and Probiotics. Front Cell Infect Microbiol. 2021 Feb 12;10:596166. doi: 10.3389/fcimb.2020.596166. eCollection 2020. Review. — View Citation

Lambert ND, Ovsyannikova IG, Pankratz VS, Jacobson RM, Poland GA. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Rev Vaccines. 2012 Aug;11(8):985-94. Review. — View Citation

Lynn DJ, Benson SC, Lynn MA, Pulendran B. Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms. Nat Rev Immunol. 2022 Jan;22(1):33-46. doi: 10.1038/s41577-021-00554-7. Epub 2021 May 17. Review. — View Citation

Ng TWY, Cowling BJ, Gao HZ, Thompson MG. Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: A Systematic Review and Meta-analysis. J Infect Dis. 2019 Apr 19;219(10):1525-1535. doi: 10.1093/infdis/jiy720. — View Citation

Trombetta CM, Remarque EJ, Mortier D, Montomoli E. Comparison of hemagglutination inhibition, single radial hemolysis, virus neutralization assays, and ELISA to detect antibody levels against seasonal influenza viruses. Influenza Other Respir Viruses. 2018 Nov;12(6):675-686. doi: 10.1111/irv.12591. Epub 2018 Aug 11. — View Citation

Yeh TL, Shih PC, Liu SJ, Lin CH, Liu JM, Lei WT, Lin CY. The influence of prebiotic or probiotic supplementation on antibody titers after influenza vaccination: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 20 — View Citation

Zimmermann P, Curtis N. The influence of probiotics on vaccine responses - A systematic review. Vaccine. 2018 Jan 4;36(2):207-213. doi: 10.1016/j.vaccine.2017.08.069. Epub 2017 Sep 18. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary IgG antibodies against vaccine influenza antigens Titer of specific total IgG antibodies against vaccine influenza A and B antigens at day 28 4 weeks (day 1 and day 28)
Secondary IgG antibodies against vaccine influenza antigens Titer of specific total IgG antibodies against vaccine influenza A and B antigens at day 56 8 weeks (day 1 and day 56)
Secondary IgM antibodies against vaccine influenza antigens Titer of specific total IgM antibodies against vaccine influenza A and B antigens at day 28 and 56 8 weeks (day 1 and day 56)
Secondary Seroconversion Percentage of patients with seroconversion (defined as 4 fold change in influenza IgG antibodies concentration compared to baseline) at day 28 and 56 8 weeks (day 1,day 28 and 56)
Secondary Incidence of influenza like infections (ILI) Cumulative incidence of influenza like infection (ILI), according to the European Diseases Prevention and Control Center (ECDC) criteria 16 weeks (day 1, day 56)
Secondary Incidence of any other respiratory infections (including COVID-19) Cumulative incidence of any other respiratory infections 16 weeks (day 1, day 56)
Secondary Incidence of fever Cumulative number of days with fever (> 37.5ÂșC) 16 weeks (day 1, day 56)
Secondary Use of analgesics and antibiotics Cumulative number of days using analgesics and antibiotics 16 weeks (day 1, day 56)
Secondary Duration of vaccine-related symptoms: injection-site pain, swelling, redness Duration (in days) of symptoms after receiving the flu vaccine. 1 week (day 1, day 7)
Secondary Severity of vaccine-related symptoms: injection-site pain, swelling, redness Severity of symptoms after receiving the flu vaccine. Measured on a 4-point scale: 0 = none , 1 = mild, 2 = moderate, and 3 = severe 1 week (day 1, day 7)
Secondary Gastrointestinal symptoms Gastrointestinal manifestations documented through questionnaire in participants diary. Measured on a 4-point scale: 0 = none , 1 = mild, 2 = moderate, and 3 = severe. 4 weeks (day 1, day 28)
Secondary Adverse events Frequency of adverse events reported in medical visits or patient diary 8 weeks (day 56)
Secondary Albumin Albumin concentration in blood 4 weeks (day 1, day 28)
Secondary Alkaline phosphatase (ALP) Alkaline phosphatase (ALP) concentration in blood 4 weeks (day 1, day 28)
Secondary Gamma-glutamil transpeptidase (GGT) Gamma-glutamil transpeptidase (GGT) concentration in blood 4 weeks (day 1, day 28)
Secondary Aspartate aminotransferase (GOT) Aspartate aminotransferase (AST) concentration in blood 4 weeks (day 1, day 28)
Secondary Alanine aminotransferase (AST) Aspartate aminotransferase (AST) concentration in blood 4 weeks (day 1, day 28)
Secondary Basic hemogram Blood cell count 4 weeks (day 1, day 28)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03285997 - A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age Phase 3
Recruiting NCT05996549 - Cost-effectiveness of the Influenza Vaccination Phase 4
Completed NCT04546854 - Influenza 2020/2021 N/A
Completed NCT01687517 - Efficacy and Safety of Influenza Vaccine During Sarcoidosis Phase 3
Completed NCT01180699 - Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients N/A
Completed NCT00760175 - Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients N/A
Completed NCT00542776 - Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine N/A
Completed NCT06304038 - Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome
Recruiting NCT04086628 - Influenza Vaccine in Children With Asthma
Completed NCT02960815 - Imiquimod and Influenza Vaccine for Immunocompromised Patients Phase 2
Completed NCT00828555 - Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting N/A
Completed NCT04230343 - Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza Vaccination Behaviour N/A
Recruiting NCT03399357 - Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial N/A
Completed NCT02153671 - Immunogenicity of H5N1 Vaccine Following H5N2 Phase 2
Completed NCT00461981 - A Phase 2 Study to Evaluate Immune Responses of FluMist® Phase 2
Recruiting NCT05070494 - Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients Phase 4
Completed NCT04785794 - Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old Phase 1
Completed NCT05163847 - Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults Phase 1
Not yet recruiting NCT04355806 - Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
Completed NCT01368796 - Comparison of 4 Influenza Vaccines in Seniors Phase 4